Biological
Secukinumab 150mg
Secukinumab 150mg is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
NCT02008890
completedphase_3
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
NCT01636687
completedphase_3
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
NCT01412944
Clinical Trials (3)
Showing 3 of 3 trials
NCT02008890Phase 3
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
NCT01636687Phase 3
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
NCT01412944Phase 3
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3